Nifty
Sensex
:
:
16266.15
54326.39
456.75 (2.89%)
1534.16 (2.91%)

Pharmaceuticals & Drugs - Global

Rating :
51/99

BSE: 524804 | NSE: AUROPHARMA

557.95
20-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  523.00
  •  559.65
  •  523.00
  •  522.85
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4256439
  •  23300.98
  •  1043.10
  •  520.85

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 32,686.59
  • 11.38
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 32,183.42
  • 0.72%
  • 1.36

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.83%
  • 0.69%
  • 8.37%
  • FII
  • DII
  • Others
  • 20.83%
  • 17.47%
  • 0.81%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.27
  • 10.69
  • 8.19

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 25.25
  • 9.20
  • 6.18

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • 18.60
  • 31.66

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.67
  • 14.75
  • 11.64

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.10
  • 2.76
  • 2.27

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 11.58
  • 9.96
  • 8.79

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Mar 21
Mar 20
Var%
Net Sales
6,002.22
6,364.91
-5.70%
5,941.92
6,483.44
-8.35%
5,701.98
5,924.78
-3.76%
6,001.50
6,158.43
-2.55%
Expenses
4,985.95
4,996.33
-0.21%
4,755.20
5,050.63
-5.85%
4,492.60
4,667.43
-3.75%
4,726.83
4,842.21
-2.38%
EBITDA
1,016.27
1,368.58
-25.74%
1,186.72
1,432.81
-17.18%
1,209.38
1,257.35
-3.82%
1,274.67
1,316.22
-3.16%
EBIDTM
16.93%
21.50%
19.97%
22.10%
21.21%
21.22%
21.24%
21.37%
Other Income
64.99
133.40
-51.28%
96.58
53.75
79.68%
109.90
115.59
-4.92%
78.10
32.59
139.64%
Interest
16.13
19.49
-17.24%
10.42
15.71
-33.67%
12.88
21.07
-38.87%
18.22
31.83
-42.76%
Depreciation
299.05
276.52
8.15%
294.21
257.34
14.33%
279.69
255.52
9.46%
266.00
232.41
14.45%
PBT
800.87
4,019.86
-80.08%
978.67
1,213.51
-19.35%
1,026.71
1,096.35
-6.35%
1,069.24
1,096.82
-2.51%
Tax
189.49
1,057.48
-82.08%
270.91
385.73
-29.77%
247.74
301.19
-17.75%
259.69
214.35
21.15%
PAT
611.38
2,962.38
-79.36%
707.76
827.78
-14.50%
778.97
795.16
-2.04%
809.55
882.47
-8.26%
PATM
10.19%
46.54%
11.91%
12.77%
13.66%
13.42%
13.49%
14.33%
EPS
10.32
50.32
-79.49%
11.90
13.79
-13.71%
13.14
13.37
-1.72%
13.68
14.75
-7.25%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
23,647.62
24,774.62
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
Net Sales Growth
-5.15%
7.26%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
 
Cost Of Goods Sold
10,023.17
8,827.71
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
Gross Profit
13,624.45
15,946.91
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
GP Margin
57.61%
64.37%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
Total Expenditure
18,960.58
19,441.22
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
Power & Fuel Cost
-
589.28
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
232.36
% Of Sales
-
2.38%
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
Employee Cost
-
3,535.02
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
% Of Sales
-
14.27%
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
Manufacturing Exp.
-
2,875.39
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
% Of Sales
-
11.61%
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
General & Admin Exp.
-
1,473.59
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
130.74
% Of Sales
-
5.95%
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
Selling & Distn. Exp.
-
1,564.17
1,524.75
1,125.76
1,025.85
848.43
877.14
878.98
359.60
305.98
208.20
% Of Sales
-
6.31%
6.60%
5.75%
6.23%
5.69%
6.36%
7.25%
4.44%
5.23%
4.50%
Miscellaneous Exp.
-
576.06
529.75
413.24
298.75
203.97
212.65
227.09
123.20
149.49
208.20
% Of Sales
-
2.33%
2.29%
2.11%
1.81%
1.37%
1.54%
1.87%
1.52%
2.55%
2.42%
EBITDA
4,687.04
5,333.40
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
EBITDA Margin
19.82%
21.53%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
Other Income
349.57
380.85
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
24.70
Interest
57.65
74.49
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
277.24
Depreciation
1,138.95
1,055.39
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
PBT
3,875.49
4,584.37
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
Tax
967.83
2,009.77
899.35
726.85
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
Tax Rate
24.97%
27.16%
23.93%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
PAT
2,907.66
5,390.20
2,860.31
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
PAT before Minority Interest
2,908.78
5,389.18
2,858.86
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
Minority Interest
1.12
1.02
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
PAT Margin
12.30%
21.76%
12.38%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
PAT Growth
-46.82%
88.45%
21.10%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
-
 
EPS
49.63
92.00
48.82
40.31
41.30
39.20
34.54
26.89
20.02
5.02
-2.11

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
21,929.87
16,824.67
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
Share Capital
58.59
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
29.11
Total Reserves
21,871.28
16,766.08
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
Non-Current Liabilities
807.17
555.09
358.13
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
Secured Loans
168.40
0.00
48.88
451.20
177.59
380.10
773.54
1,101.31
1,084.11
862.08
Unsecured Loans
0.00
0.00
131.07
0.00
3.81
362.71
587.93
178.05
64.15
102.55
Long Term Provisions
157.11
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
4.24
Current Liabilities
10,665.15
11,384.64
12,020.57
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
Trade Payables
2,794.68
2,576.06
2,552.18
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
Other Current Liabilities
2,685.47
2,874.56
2,510.51
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
Short Term Borrowings
4,802.71
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
Short Term Provisions
382.29
511.72
384.67
294.23
261.36
132.93
218.24
126.60
80.09
66.36
Total Liabilities
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
Net Block
9,373.58
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
Gross Block
13,613.33
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
Accumulated Depreciation
4,239.75
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
Non Current Assets
13,577.80
12,352.03
10,938.77
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
Capital Work in Progress
3,061.53
1,985.92
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
Non Current Investment
431.22
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
19.86
Long Term Loans & Adv.
658.44
378.34
396.64
261.91
256.48
236.56
455.27
789.04
237.82
108.12
Other Non Current Assets
53.03
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
0.12
Current Assets
19,823.51
16,412.51
15,332.30
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
Current Investments
159.79
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
18.68
Inventories
9,026.57
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
Sundry Debtors
3,503.28
4,315.16
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
Cash & Bank
5,474.28
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
70.86
Other Current Assets
1,659.59
489.35
1,919.82
1,223.32
1,596.81
831.25
659.57
448.46
407.69
388.98
Short Term Loans & Adv.
1,058.30
1,065.96
795.90
753.96
512.09
366.88
387.90
237.22
207.51
216.67
Net Current Assets
9,158.36
5,027.87
3,311.73
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
Total Assets
33,401.31
28,764.54
26,271.07
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
3,328.92
4,381.28
1,650.97
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
PBT
7,343.59
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
Adjustment
-1,662.64
1,091.17
813.95
535.02
408.92
487.50
406.28
515.12
441.54
387.22
Changes in Working Capital
-1,066.78
307.91
-1,484.50
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
Cash after chg. in Working capital
4,614.17
5,142.12
2,420.80
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-1,285.25
-760.84
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
598.69
-1,567.64
-2,902.59
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
Net Fixed Assets
-428.04
-760.60
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
Net Investments
-2,482.52
-188.35
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
Others
3,509.25
-618.69
-1,732.03
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
Cash from Financing Activity
-1,364.81
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
Net Cash Inflow / Outflow
2,562.80
866.46
667.44
892.08
-423.72
339.99
-67.95
-54.82
136.62
-118.06
Opening Cash & Equivalents
2,746.82
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
183.71
Closing Cash & Equivalent
5,329.91
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73
65.64

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
374.29
287.16
237.08
199.36
159.96
124.50
88.29
64.33
44.74
40.19
ROA
17.34%
10.39%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
ROE
27.81%
18.62%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
ROCE
30.33%
18.79%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
Fixed Asset Turnover
3.73
4.12
4.36
2.44
2.96
2.79
2.55
2.08
1.75
1.71
Receivable days
29.37
29.85
29.56
64.66
89.16
106.53
91.84
93.55
86.28
95.44
Inventory Days
62.82
57.72
59.64
112.70
101.43
100.27
88.91
94.82
105.51
115.91
Payable days
111.03
53.30
58.56
67.77
75.73
81.70
67.49
71.06
57.79
64.70
Cash Conversion Cycle
-18.84
34.27
30.63
109.58
114.86
125.10
113.25
117.31
134.00
146.65
Total Debt/Equity
0.23
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
Interest Cover
100.33
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40
0.23

News Update:


  • Aurobindo Pharma gets 6 observations from USFDA for Unit VII
    11th May 2022, 09:46 AM

    The company will respond to the USFDA within the stipulated timeline and work closely with USFDA to close the observations.

    Read More
  • Aurobindo Pharma’s unit recalls Cyanocobalamin Injection in US market
    25th Apr 2022, 09:28 AM

    Aurobindo Pharma USA Inc is recalling 4,33,809 vials of Cyanocobalamin injection for being a ‘Subpotent Drug’

    Read More
  • Aurobindo Pharma gets approval for acquisition of business and certain assets of Veritaz
    29th Mar 2022, 09:46 AM

    The Board of Directors of the Company at its meeting held on March 28, 2022 has approved the same

    Read More
  • Aurobindo Pharma’s unit recalls Moxifloxacin Ophthalmic Solution in US market
    28th Feb 2022, 09:30 AM

    According to the USFDA, Aurobindo Pharma USA Inc is recalling the affected lot due to ‘failed impurities/degradation specifications’

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.